{'52WeekChange': 1.2573023,
 'SandP52WeekChange': 0.0644362,
 'address1': '220 East Grand Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 85.09,
 'askSize': 800,
 'averageDailyVolume10Day': 1163787,
 'averageVolume': 473292,
 'averageVolume10days': 1163787,
 'beta': None,
 'beta3Year': None,
 'bid': 83.4,
 'bidSize': 1200,
 'bookValue': 10.036,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 85.91,
 'dayLow': 82.58,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -33.051,
 'enterpriseToRevenue': 83.749,
 'enterpriseValue': 2512460800,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 65.720856,
 'fiftyTwoWeekHigh': 94.91,
 'fiftyTwoWeekLow': 25.35,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 22837111,
 'forwardEps': -4.2,
 'forwardPE': -20.240479,
 'fromCurrency': None,
 'fullTimeEmployees': 105,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0139,
 'heldPercentInstitutions': 1.00781,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/principiabio.com',
 'longBusinessSummary': 'Principia Biopharma Inc., a late-stage '
                        'biopharmaceutical company, focuses on developing '
                        'novel therapies for immune-mediated diseases. The '
                        'company is developing rilzabrutinib, an inhibitor '
                        'that is in Phase III clinical trials for the '
                        'treatment of pemphigus, a chronic skin disease, as '
                        'well as and pemphigus foliaceus; in a Phase 1/2 trial '
                        'for the treatment of immune thrombocytopenia; and a '
                        'Phase 2 trial for the treatment of IgG4-related '
                        'disease. It is also developing PRN2246/SAR442168, an '
                        'inhibitor, which is in Phase Ii clinical trial for '
                        'treating multiple sclerosis (MS) and other central '
                        'nervous system (CNS) diseases; and PRN473, a drug '
                        'candidate that is in Phase I clinical trial for the '
                        'treatment of immune-medicated diseases. The company '
                        'has a collaboration agreement with Genzyme '
                        'Corporation to develop relapsing and progressive MS '
                        'and other diseases of the CNS. Principia Biopharma '
                        'Inc. was incorporated in 2008 and is headquartered in '
                        'South San Francisco, California.',
 'longName': 'Principia Biopharma Inc.',
 'market': 'us_market',
 'marketCap': 2808798464,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_127531987',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -72604000,
 'nextFiscalYearEnd': 1640908800,
 'open': 83.53,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.51,
 'phone': '650 416 7700',
 'previousClose': 85.92,
 'priceHint': 2,
 'priceToBook': 8.470506,
 'priceToSalesTrailing12Months': 93.62662,
 'profitMargins': -2.42013,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 85.91,
 'regularMarketDayLow': 82.58,
 'regularMarketOpen': 83.53,
 'regularMarketPreviousClose': 85.92,
 'regularMarketPrice': 83.53,
 'regularMarketVolume': 517062,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 33040800,
 'sharesPercentSharesOut': 0.1016,
 'sharesShort': 3357840,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2168002,
 'shortName': 'Principia Biopharma Inc.',
 'shortPercentOfFloat': 0.1387,
 'shortRatio': 7.17,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'PRNB',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.59,
 'twoHundredDayAverage': 61.561584,
 'volume': 517062,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.principiabio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}